US equities
|
MU
$928.76
▲+0.00%
SNDK
$1,304.84
▲+0.00%
SKHY
$145.36
▲+0.00%
TSLA
$407.46
▲+0.00%
NVDA
$217.94
▲+0.00%
INTC
$93.74
▲+0.00%
GOOGL
$320.58
▲+0.00%
STX
$667.85
▲+0.00%
MU
$928.76
▲+0.00%
SNDK
$1,304.84
▲+0.00%
SKHY
$145.36
▲+0.00%
TSLA
$407.46
▲+0.00%
NVDA
$217.94
▲+0.00%
INTC
$93.74
▲+0.00%
GOOGL
$320.58
▲+0.00%
STX
$667.85
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Forma Therapeutics Holdings, Inc. - Common Stock
(NQ:
FMTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 13, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Forma Therapeutics Holdings, Inc. - Common Stock
< Previous
1
2
3
Next >
Forma Therapeutics Announces Appointment of New Executive Team Members
June 30, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Read Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'
↗
June 13, 2022
Via
Benzinga
Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
June 10, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Present at the Jefferies Healthcare Conference
June 03, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Recap: Forma Therapeutics Hldgs Q1 Earnings
↗
May 06, 2022
Forma Therapeutics Hldgs (NASDAQ:FMTX) reported its Q1 earnings results on Friday, May 6, 2022 at 07:05 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
May 26, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 06, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Preview: Forma Therapeutics Hldgs's Earnings
↗
May 05, 2022
Forma Therapeutics Hldgs (NASDAQ:FMTX) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
April 29, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Earnings Scheduled For March 1, 2022
↗
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Earnings Scheduled For May 6, 2022
↗
May 06, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion.
Via
Benzinga
Forma Therapeutics: Q4 Earnings Insights
↗
March 01, 2022
Forma Therapeutics Hldgs (NASDAQ:FMTX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:05 AM. Here's what investors need to know about the announcement...
Via
Benzinga
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
February 23, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
February 08, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
January 13, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 07, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
December 16, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
December 11, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
December 09, 2021
From
Forma Therapeutics
Via
Business Wire
Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
November 30, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
↗
November 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
↗
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Earnings Scheduled For November 12, 2021
↗
November 12, 2021
Companies Reporting Before The Bell • Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million. • Natura &Co...
Via
Benzinga
Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
November 05, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
November 04, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
↗
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
↗
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
45 Biggest Movers From Yesterday
↗
October 08, 2021
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial...
Via
Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
↗
October 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...
Via
Benzinga
< Previous
1
2
3
Next >
